The call ran from 12:31 PM to 1:30 PM IST (59 min).
Key takeaways
Anthem delivered robust Q2 results driven by CRDMO business and sharp margin expansion. Management highlighted strong operating leverage and cost discipline while scaling capacity.
| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | ₹594 Cr in Q2, 8% growth for the quarter. |
|---|---|
| Margins | EBITDA margins expanded significantly to 50.6% due to operating leverage. |
| Demand visibility | Underlying demand remains strong across CRDMO and specialty ingredients. |
| Management confidence | Extremely confident, emphasizing industry-leading margins and robust performance. |
Growth
Revenue grew 8% QoQ to ₹594 Cr, while EBITDA margins surged to 50.6%.
Outlook
Ongoing ₹1,200 Cr Capex for Unit 4 to double current capacity by FY28.
Risks
High client concentration with top 10 contributing 80% of revenue. Regulatory dependence on China sourcing remains at 21%.
Last quarter's promises, checked
Delivered
- Guided Q1 as softest qtr, Q2 recovery → Q2 rev ₹594 Cr vs Q1 ₹418 Cr (= BEAT)
- Guided Q1 EBITDA 39.6% held → Q2 EBITDA 50.6% (= BEAT)
- Guided CRDMO recovery from Q1 ₹341 Cr → Q2 ₹509 Cr (= BEAT)
Partly delivered
- Guided ₹1,200 Cr Unit 4 capex over FY27-28 → reaffirmed ₹1,200 Cr, no spend-to-date (= PARTIAL)
- Guided specialty 'very decent growth' → ₹78 Cr to ₹85 Cr, +9% (= PARTIAL)
- Guided 'double-digit' historical growth → FY27 guide +10.0% YoY, at floor (= PARTIAL)
Summary by ALFA Finder, written with AI assistance from our own recording of the call, published . Open it on ALFA Filings ›
The results behind this call
Anthem Biosciences Q2 FY27 Results: Net Profit ₹211.5 Cr, Up 22.0% YoY
Anthem Biosciences Ltd reported revenue from operations of ₹594 Cr (+7.9% YoY) and net profit of ₹211.5 Cr (+22.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹211.5 Cr · +22.0% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
Unit 4 commissioning expected by end of FY28; management anticipates historical double-digit growth rates for full FY27.
Growth they described
Revenue de-grew 25% YoY to ₹418 Cr; EBITDA margins improved YoY through cost optimization and better mix.
Call details
| Company | Anthem Biosciences Ltd |
|---|---|
| NSE symbol | ANTHEM |
| ISIN | INE0CZ201020 |
| Call | Q2 FY27 earnings call |
| Date | Wednesday, 4 November 2026 |
| Time | 12:30 PM IST |
| Length | 59 min |
| Audio | Our stream on YouTube ↗ |
Anthem Biosciences Ltd: key numbers
- Share price
- ₹888.30
- Market cap
- ₹50,029 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 81.5×Sector 41.3×
- Promoter holding
- 71.40%-0.02% QoQ
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Wed, 4 Nov
Today's concalls →
